The Cellular Therapies Program at Smilow Cancer Hospital is led by Stuart Seropian, MD, Professor of Medicine (Hematology), Iris Isufi , MD, Associate Professor of Medicine (Hematology), and Michael Hurwitz, MD, PhD, Associate Professor of Medicine (Medical Oncology). Alex Dormal, RN, BSN, program manager, is available to assist with referrals and to help patients navigate their care. Together with their colleagues, they are leading clinical trials to advance the field of cellular therapies and discover additional treatment options for more types of cancer. This allows patients at Smilow Cancer Hospital some of the earliest access to novel cellular therapies and provides our team with exclusive experience delivering cellular therapies.

A comprehensive, multidisciplinary team is involved in the care of patients receiving these therapies, including a transplant team, a cell collection and processing unit, the Intensive Care Unit, pharmacy, social work, and access to telehealth for home evaluations. All patients are closely monitored for any side effects following therapy, and patients and families are given extensive education on how to safely continue care at home.

The Cellular Therapies Program at Smilow Cancer Hospital develops and delivers cell-based treatments to patients with cancer and other benign hematological diseases, including Chimeric Antigen Receptor T-Cell (CAR-T) Therapy, Tumor-Infiltrating Lymphocytes (TILs), and Gene Therapy. Current FDA-approved treatments available are:

CAR-T Therapy for Hematological Malignancies:

Large B-cell Lymphoma

Diffuse large B-cell Lymphoma

High-grade B-cell Lymphoma

Primary Mediastinal Large B-Cell Lymphoma

Follicular Lymphoma

Chronic Lymphocytic Leukemia

Small Lymphocytic Lymphoma

Refractory Follicular Lymphoma

Relapsed or Refractory Mantle Cell Lymphoma

Acute Lymphoblastic Leukemia

Multiple Myeloma

TIL Therapy for Solid Tumors:

Metastatic Melanoma

Gene Therapy Classical Hematology:

Sickle Cell Disease

B-Thalassemia